Allogene Therapeutics Inc (ALLO)
3.07
+0.10
(+3.37%)
USD |
NASDAQ |
May 03, 16:00
3.065
0.00 (0.00%)
Pre-Market: 20:00
Allogene Therapeutics Shareholders Equity (Quarterly): 512.23M for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 512.23M |
| September 30, 2023 | 583.10M |
| June 30, 2023 | 622.91M |
| March 31, 2023 | 592.26M |
| December 31, 2022 | 666.88M |
| September 30, 2022 | 739.96M |
| June 30, 2022 | 801.95M |
| March 31, 2022 | 855.23M |
| December 31, 2021 | 925.20M |
| September 30, 2021 | 969.94M |
| June 30, 2021 | 1.024B |
| March 31, 2021 | 1.070B |
| Date | Value |
|---|---|
| December 31, 2020 | 1.080B |
| September 30, 2020 | 1.119B |
| June 30, 2020 | 1.163B |
| March 31, 2020 | 606.52M |
| December 31, 2019 | 629.02M |
| September 30, 2019 | 619.72M |
| June 30, 2019 | 655.64M |
| March 31, 2019 | 681.23M |
| December 31, 2018 | 703.16M |
| September 30, 2018 | -168.44M |
| June 30, 2018 | 281.61M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
512.23M
Minimum
Dec 2023
1.163B
Maximum
Jun 2020
801.89M
Average
739.96M
Median
Sep 2022
Shareholders Equity (Quarterly) Benchmarks
| Agenus Inc | -160.33M |
| ANI Pharmaceuticals Inc | 457.60M |
| Vaxart Inc | 57.80M |
| aTyr Pharma Inc | 90.66M |
| PAVmed Inc | -53.83M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 642.84M |
| Total Liabilities (Quarterly) | 130.60M |
| Current Ratio | 12.38 |